Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3F8 and GM-CSF for high-risk neuroblastoma consolidation
NCT01183429Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2010
- Primary completion
- Sep 2018
- Countries
- 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Conditions
- neuroblastoma
01
Overview
Phase 2, open-label trial of anti-GD2 monoclonal antibody 3F8 in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Assess the Impact of High-dose 3F8/GM-CSF at 2 years. Started Aug 2010; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients with high-risk neuroblastoma in first CR/VGPR after conventional therapy, with no measurable MIBG-avid soft tissue tumor.
04
Endpoints
Primary
Assess the Impact of High-dose 3F8/GM-CSF
Beyond the preview
Go deeper on NCT01183429.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01183429.